LCDX (Caliber Imaging & Diagnostics) Beta: -0.1220 (As of Jun. 25, 2026)


What is Caliber Imaging & Diagnostics Beta?

Caliber Imaging & Diagnostics LCDX Beta is -0.1220 as of Jun. 25, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Caliber Imaging & Diagnostics's Beta is -0.1220.

Caliber Imaging & Diagnostics  (OTCPK:LCDX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Caliber Imaging & Diagnostics Beta Related Terms

Caliber Imaging & Diagnostics Beta Historical Data

* Premium members only.

The historical data trend for Caliber Imaging & Diagnostics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caliber Imaging & Diagnostics Beta Chart

Caliber Imaging & Diagnostics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13
Beta
0.00 0.00 0.00 0.00 0.00

Caliber Imaging & Diagnostics Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LCDX vs VICA, CRVW, RSLS: Beta Comparison

For the Medical Devices subindustry, Caliber Imaging & Diagnostics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Caliber Imaging & Diagnostics Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Caliber Imaging & Diagnostics's Beta distribution charts can be found below:

* The bar in red indicates where Caliber Imaging & Diagnostics's Beta falls into.


Caliber Imaging & Diagnostics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.1220 mean?
Caliber Imaging & Diagnostics (LCDX) has a Beta of -0.1220 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Caliber Imaging & Diagnostics and its competitors.
Is Caliber Imaging & Diagnostics' Beta too high?
Caliber Imaging & Diagnostics' current Beta is -0.1220.
How does Caliber Imaging & Diagnostics' Beta compare to VICA and CRVW?
Caliber Imaging & Diagnostics' Beta of -0.1220 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Caliber Imaging & Diagnostics and its competitors. Caliber Imaging & Diagnostics's current Beta is -0.1220. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliber Imaging & Diagnostics stock overvalued right now?
Caliber Imaging & Diagnostics (LCDX) has a current Beta of -0.1220. The current Beta is -0.1220. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Caliber Imaging & Diagnostics (LCDX), the current Beta is -0.1220 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Caliber Imaging & Diagnostics Business Description

Address 50 Methodist Hill Drive, Suite 1000, Rochester, NY, USA, 14623
Caliber Imaging & Diagnostics Inc is a medical device company engaged in developing, manufacturing, marketing & selling point-of-care cellular imaging systems to diagnose skin cancer. It offers clinical imaging and research imaging solutions that shows tissue at the cellular level. Its products portfolio includes; VivaScope; VivaScope 3000, 1500 & 2500; and VivaNet and VivaScan.